eli lilly phase 3 trial retatrutide Lilly's triple agonist delivers up to 71.2 lbs of weight loss

Eli Lilly infiltrates anti-obesity market as Phase III trial for retatrutide begins

28.70

★★★★☆4.8 (126)

New Phase 3 retatrutide data just dropped 👀 Eli Lilly's trial reported average weight loss approaching 30%, with some patients achieving results historically associated with bariatric surgery. A few important caveats: •

25.46

★★★★★4.9 (98)

Eli Lilly's Retatrutide Weight Loss Trial Stuns In Phase 3

25.50

★★★★★5.0 (157)

Lilly's triple agonist achieves 16.8% weight loss in phase 3 trial

27.61

★★★★★4.7 (84)

Today we shared new results on retatrutide, an investigational, first-of-its-kind treatment we're studying in adults with obesity or overweight with at least one weight-related comorbidity. Read more about the Phase 3 findings:

20.39

★★★★★4.9 (203)

Retatrutide, an experimental drug currently in Phase 3 clinical trials, is nicknamed the Godzilla of weight-loss jabs because of its potential superior efficacy. Developed by Eli Lilly, retatrutide is a triple hormone

26.02

★★★★★5.0 (176)

Rachel the Dietitian_ Redefining Menopause for Our Generation | Eli Lilly announced promising Phase 3 trial results for retatrutide, a next-generation obesity medication targeting THREE metabolic

20.28

★★★★★4.8 (132)